Click to close

Contact us

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Request a Demo

Please complete the required fields.

*Required Fields

Request a Demo

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Click to close

Report Problem

Please complete the required fields.

*Required Fields

Send

US Toll-free: 1-888-286-4003 International: 1-978-347-1143 contact@visresearch.com

Login

Click to close

Please complete the required fields.

Forgot your password? Register

Tell us your email address and we'll send you instructions on how to reset your password.

Click to close

Resolution not supported

Click to close

Saving...

 0%

Institutul de Pneumoftiziologie Marius Nasta

Şoseaua Viilor 90, Sector 5, Bucureşti, Bucureşti - Ilfov
050159
Romania
Website | ViS Profile

Center Profile Completeness

About
- Center
- Location
Infrastructure
- General
- Disease-Specific
Patients
- General
- Disease-Specific
Team
- Personnel
- Investigators
Expertise
- General
- Disease-Specific
Research
- Trials
- Publications
Network
- Disease-Specific

Trials in this area

- Long-term Extension Study of the SERAPHIN Study, to Assess the Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension (Actelion; NCT00667823; Year 2008)

- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension, GRIPHON Trial (Actelion; NCT01106014; Year 2009)

- Safety & Efficacy of BCT197A2201 in Chronic Obstructive Pulmonary Disease (COPD) Patients Presenting With an Exacerbation (Novartis Pharmaceuticals; NCT01332097; Year 2011)

- Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) (Novartis Pharmaceuticals; NCT01636076; Year 2012)

- The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 Mcg Once Daily Compared With Tiotriopium 18 Mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD. (GlaxoSmithKline; NCT01777334; Year 2013)

Investigators in this area

  • Miron Bogdan
  • Florin Mihaltan
  • Roxandra Ulmeanu
  • Paul Stoicescu

Diseases in this area

  • Sleep Apnea
  • COPD
  • Sinusitis
  • Asthma
  • Pulmonary Embolism
  • Pulmonary Vascular Disorder
  • Pulmonary Hypertension
  • Peripheral Vascular Disease

Click to close
Click to close

Add to network